Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
Additional reported applications (for the relevant formats) include: The DJR2-4 antibody is useful for immunofluorescent staining and flow cytometric analysis of DR5/TRAIL-R2 receptor expression. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 307406) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated antibody (Cat. No. 307404) or biotinylated anti-mouse IgG second step (Cat. No. 405303), followed by SAv-PE (Cat. No. 405204)).
Application References:
1. Uno, K., et al., 2003. Blood 101: 3658. 2. Sato, K., et al., 2005. J. Immunol. 174:4025. 3. Lundgvist, A.,et al.2006.Cancer Res.14:7317.PubMed
Human peripheral blood lymphocytes stained with purified DJR2-4, followed by biotinylated anti-mouse IgG and Sav-PE
Description:
DR5 is 55 kD member 10B of the TNF receptor superfamily (TNFRSF10B), also known as TRAIL-R2, TRICK2, KILLER, and CD262. It binds the cytotoxic ligand TRAIL and induces apoptosis. The DR5 receptor is broadly expressed on a variety of normal tissues and many tumors. DR5 expression has been reported to be upregulated in human cells by interferon-α, 2-methoxyestradiol, and paclitaxel, and downregulated by adenoviral E3 proteins.
Other Names:
TRAIL-R2, KILLER, TRICK2, TNFRSF10B, Ly98, CD262
Structure:
TNFR superfamily, 55 kD
Distribution:
Broadly expressed on normal and tumor cells
Function:
Induces apoptosis
Ligand Receptor:
TRAIL
Antigen References:
1. MacFarlane, M., et al., 1997. J. Biol. Chem. 272:25417. 2. Walczak, H., et al., 1997. EMBO J. 16:5386. 3. Shigeno, M., et al., 2003. Oncogene 22:1653. 4. LaVallee, T., et al., 2003. Cancer Res. 63:468. 5. Nimmanapalli, R., et al., 2001. Cancer Res. 61:759
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
